April 22, 2020 10:22 AM

AUROBINDO PHARMA share price has zoomed 6% and is presently trading at Rs 684.

Meanwhile, the BSE HEALTHCARE Index is at 15,271 (up 0.9%).

Among the top Gainers in the BSE HEALTHCARE Index today are AUROBINDO PHARMA (up 6.1%) and LAURUS LABS LTD (up 5.5%).

J.B.CHEMICALS (down 0.1%) and GSK PHARMA (down 0.3%) are among the top losers today.

Over the last one year, AUROBINDO PHARMA has moved down from Rs 779 to Rs 684, registering a loss of Rs 94 (down 12.2%).

On the other hand, the BSE HEALTHCARE has moved up from 14,308 to 15,271, registering a gain of 963 points (up 6.5%) during the last 12 months.

The top gainers among the BSE HEALTHCARE Index stocks during this same period were ABBOTT INDIA (up 115.8%), J.B.CHEMICALS (up 63.5%) and IPCA LABS (up 63.3%).

What About the Benchmark Indices?

The BSE Sensex is at 30,856 (up 0.2%).

The top gainers among the BSE Sensex stocks today are RELIANCE IND. (up 6.1%), HERO MOTOCORP (up 3.0%) and ASIAN PAINTS (up 2.2%). Other gainers include SUN PHARMA (up 1.6%) and MARUTI SUZUKI (up 1.4%). The most traded stocks in the BSE Sensex are RELIANCE IND. and ITC.

In the meantime, NSE Nifty is at 9,031 (up 0.1%). The top gainers in the NSE Nifty include RELIANCE IND. (up 6.4%), ZEE ENTERTAINMENT (up 5.6%) and HERO MOTOCORP (up 3.4%). Other gainers include ASIAN PAINTS (up 2.2%) and BHARTI INFRATEL (up 2.0%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved down from 38,645 to 30,856, registering a loss of 7,789 points (down 20.57%).

AUROBINDO PHARMA Financial Update...

AUROBINDO PHARMA net profit down at Rs 7 billion for the quarter ended December 2019, compared to a loss of Rs 7 billion a year ago. Net Sales rose 10.1% to Rs 58.0 billion during the period as against Rs 52.7 billion in October-December 2018.

For the year ended March 2019, AUROBINDO PHARMA reported 1.2% increase in net profit to Rs 24.5 billion compared to net profit of Rs 24.2 billion during FY18.

Revenue of the company grew 18.6% to Rs 196 billion during FY19.

The current Price to earnings ratio of AUROBINDO PHARMA, based on rolling 12 month earnings, stands at 15.6x.